List of Izba drug patents

Izba is owned by Novartis.

Izba contains Travoprost.

Izba has a total of 4 drug patents out of which 0 drug patents have expired.

Izba was authorised for market use on 15 May, 2014.

Izba is available in solution/drops;ophthalmic dosage forms.

The generics of Izba are possible to be released after 10 October, 2029.

IZBA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Mar, 2029

(5 years from now)

US8754123 NOVARTIS Pharmaceutical compositions having desirable bioavailability
May, 2029

(6 years from now)

US8722735 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(6 years from now)

US8178582 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(6 years from now)

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of IZBA before it's patent expiration?
More Information on Dosage

IZBA family patents

8

United States

4

European Union

3

Denmark

3

Spain

2

Hong Kong

2

Germany

2

China

2

Japan

1

South Africa

1

Mexico

1

Australia

1

Russia

1

Slovenia

1

Hungary

1

Uruguay

1

Argentina

1

Brazil

1

Portugal

1

Korea, Republic of

1

Poland

1

Chile

1

Taiwan, Province of China

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic